Skip to main content
Figure 8 | Cancer & Metabolism

Figure 8

From: Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations

Figure 8

Inhibition of mammary tumor cell growth by targeting nicotinamide phosphoribosyltransferase (NAMPT). Tissue sections from mouse breast tumor nodes in MMTV-TGFα transgenic (Tg) mice (A), FGFR4−/−: MMTV-TGFα bigenic (KO-Tg) mice (B) and normal breast (C), or from human breast tumor (D) and matched normal breast (E) were analyzed for NAMPT expression (blue arrow, orange staining) by IHC, examined under microscope and representative sections were shown. Tumor cells were isolated from established solid tumor foci in Tg and KO-Tg mice, cultured for one day and then treated with vesicle dimethyl sulfoxide (DMSO), 5 μM FK866 or 5 μM Triptolide for 5 days. Treatment with FK866, a catalytic inhibitor for NAMPT, significantly reduced the population growth of primary tumor cells (F). Light blue line: vesicle DMSO; green line: 5 μM FK866; black line: 5 μM Triptolide as positive control; Filled shapes (square, triangle and circle): tumor cells from Tg mice; open shapes: tumor cells from KO-Tg mice.

Back to article page